Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Rapid Next-Gen Sequencing Method Predicts Prostate Cancer Risks

By LabMedica International staff writers
Posted on 08 Jan 2019
Prostate cancer is the most commonly diagnosed male cancer and the second leading cause of cancer deaths among men in the USA, with approximately 220,000 new diagnoses and approximately 27,000 deaths each year.

Men with clinical low-risk disease can receive active surveillance to safely preserve quality of life, provided that the risk of an undetected aggressive cancer can be managed. Clinical tests for the prognosis of prostate cancer from radical prostatectomy specimens and biopsy specimens are being increasingly used to inform treatment and active surveillance protocols.

A team of scientists led by those at the Albert Einstein College of Medicine (Bronx, NY, USA) collected from prostate cancer radical prostatectomy cohort of 72 men was collected at Duke University. A total of 88 prostate cancer surgical research (PCSR) samples (from 69 unique men) and 21 healthy samples were microdissected and underwent DNA extraction. A second prostate cancer cohort comprised 12 PCSR samples with matched punched biopsy samples (Duke Cohort 2). All PCSR samples (Duke Cohorts 1 and 2) were assayed on the OncoScan formalin-fixed, paraffin-embedded (FFPE) version 3 array and on the Next Generation Copy Number Alteration NG-CNA panel.

The team developed a genomic DNA signature, the metastatic potential score (MPS), and verified it as highly predictive of prostate cancer, triple-negative breast cancer, and lung adenocarcinoma metastases using surgical samples. Metastases and metastasis-prone primary tumors demonstrated enrichment of specific CNAs in one direction, either gain or loss. This directionality provided a basis for calculating scores for the specific genes within the CNA regions that included a penalty when the CNA went against the expected directionality.

The team reported that the NG-CAN assay can analyze 902 genomic sites across 194 genomic regions, which it can do both faster than existing tests and at a lower cost. With the NG-CNA, the cost of DNA extraction, library preparation, and sequencing reagents can be USD 20 to USD 40 per sample, compared to nearly USD 1,000 for whole genome sequencing. The team noted that the results that they obtain through the new test are easier to read, allowing scientists to process thousands of tissue samples in one go. NG-CNA also has a quicker turnaround time for the results, at approximately 36 hours. Finally, NG-CNA calls for the collection of smaller samples than other tests currently in use. The sample size can be as low as 12.5 ng of material, which would allow specialists to use the test to analyze cell lines, biopsy samples, and surgical samples.

Harry Ostrer, MD, a medical geneticist and lead author of the study said, “We have demonstrated that CNAs can be detected rapidly and accurately with the new Next-Generation Copy Number Alteration (NG-CNA) assay. We believe the addition of the NG-CNA assay onto a standard cancer gene testing platform will augment personalized medicine by identifying aggressive tumors and genetic mutations that are predictors of response to targeted therapies.” The study was published on December 12, 2018, in The Journal of Molecular Diagnostics.

Related Links:
Albert Einstein College of Medicine


Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
cTnI/CK-MB/Myo Test
Finecare cTnI/CK-MB/Myo Rapid Quantitative Test
New
Biological Indicator Vials
BI-O.K.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.